Clinical trials: Synovial Sarcomas
Ewing's Sarcoma, Rhabdomyosarcoma
Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy
Filgrastim (granulocyte colony-stimulating factor), which is administered by daily subcutaneous injection after cytotoxic chemotherapy, shortens the duration of chemotherapy-induced neutropenia and lowers the risk of infection.
- Conditions
- Ewing's Sarcoma, Rhabdomyosarcoma, MPNST, Synovial Sarcoma
- Trial name
- NCT00004853
- Testing
- Filgrastim, Filgrastim-SD/01
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy, such as ifosfamide and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00334854
- Testing
- doxorubicin hydrochloride, ifosfamide, adjuvant therapy
- Where
- 28 sites in Austria, Belgium and 7 more
- Volunteers
- 250 people
- Sponsor
- European Paediatric Soft Tissue Sarcoma Study Group
Sarcoma, Synovial
First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10
Advanced synovial sarcoma represents an unmet medical need. The gene encoding frizzled homologue 10 (FZD10), a 7-transmenbrane receptor, member of the Wnt signalling receptor family, is overexpressed in SS and is undetectable in…
- Trial name
- SYNFRIZZ (NCT01469975)
- Testing
- OTSA101-DTPA-90Y level 1, OTSA101-DTPA-90Y level 2, OTSA101-DTPA-90Y level 3
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Leon Berard
Sarcoma, Fibrosarcoma
Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall
After a screening, which consists of biopsy, physical examination, initial diffusion-weighted magnetic resonance imaging (DWI-MRI), body computed tomography (CT) scan, blood tests and case analysis on Multidisciplinary Team (MDT)…
- Conditions
- Sarcoma, Fibrosarcoma, Leiomyosarcoma, Liposarcoma
- Trial name
- UN-RESARC (NCT03651375)
- Testing
- Sequential chemotherapy - 3 courses of AI, Hypofractionated radiotherapy
- Where
- Poland
- Volunteers
- 46 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
B-cell Acute Lymphoblastic Leukemia, Lymphoma
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Lymphoma, Myeloid Leukemia, Multiple Myeloma
- Trial name
- NCT03638206
- Testing
- CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Shenzhen BinDeBio Ltd.
Synovial Sarcoma, Sarcoma, Synovial
DHEA in Synovial Sarcoma Patients
DHEA is a natural allosteric inhibitor of glucose-6-phosphate dehydrogenase (G6PD). G6PD is a key regulatory enzyme for the survival of synovial sarcoma.
- Trial name
- NCT02683148
- Testing
- DHEA, FACT-67 validated survey
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Washington University School of Medicine
Childhood Alveolar Soft Part Sarcoma, Childhood Angiosarcoma
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
This phase II trial studies how well cixutumumab and temsirolimus work in treating patients with recurrent or refractory sarcoma. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways.
- Conditions
- Childhood Alveolar Soft Part Sarcoma, Childhood Angiosarcoma, Childhood Epithelioid Sarcoma, Childhood Fibrosarcoma
- Trial name
- NCT01614795
- Testing
- Cixutumumab, Laboratory Biomarker Analysis, Temsirolimus
- Where
- 76 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Chondrosarcoma
A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)
This is a multicenter, open-label, Phase II trial designed to evaluate the efficacy and safety of PRO95780 when given as a single agent in patients with advanced chondrosarcoma.
- Trial name
- NCT00543712
- Testing
- PRO95780
- Where
- 4 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Genentech, Inc.
Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK)
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
This study will include participants with various types of cancer known as soft-tissue sarcomas. Tissues that can be affected by soft tissue sarcomas include fat, muscle, blood vessels, deep skin tissues, tendons and ligaments.
- Conditions
- Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), Selected Tumors With Rhabdoid Features
- Trial name
- NCT02601950
- Testing
- Tazemetostat
- Where
- 32 sites in United States, Australia and 7 more
- Volunteers
- 267 people
- Sponsor
- Epizyme, Inc.
Rhabdoid Tumors, INI1-negative Tumors
EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
This is a Phase I, open-label, dose escalation and dose expansion study with BID (suspension) and TID (tablet) oral dose of the enhancer of zeste homolog-2 (EZH2) inhibitor, tazemetostat.
- Conditions
- Rhabdoid Tumors, INI1-negative Tumors, Synovial Sarcoma, Malignant Rhabdoid Tumor of Ovary
- Trial name
- NCT02601937
- Testing
- Tazemetostat
- Where
- 35 sites in United States, Australia and 7 more
- Volunteers
- 109 people
- Sponsor
- Epizyme, Inc.
Soft Tissue Sarcoma
Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma
The purpose of this study is to investigate whether the addition of oral maintenance chemotherapy with O-TIE (Etoposide, Idarubicin, Trofosfamide) for 6 months improves the event free survival (EFS) in patients with localised…
- Trial name
- CWS-2007-HR (NCT00876031)
- Testing
- trofosfamide, idarubicin, etoposide
- Where
- 87 sites in Austria, Germany and 3 more
- Volunteers
- 195 people
- Sponsor
- University Hospital Tuebingen
Pediatric Solid Tumor, Germ Cell Tumor
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
This is a phase I, open-label, non-randomized study that will enroll pediatric and young adult research participants with relapsed or refractory non-CNS solid tumors to evaluate the safety, feasibility, and efficacy of…
- Conditions
- Pediatric Solid Tumor, Germ Cell Tumor, Retinoblastoma, Hepatoblastoma
- Trial name
- NCT03618381
- Testing
- second generation 4-1BBζ EGFR806-EGFRt, second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Seattle Children's Hospital
Solid Tumors, Sarcoma
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
This 2-part study will evaluate safety, tolerability, and clinical efficacy of DS-2243a as a treatment for participants with advanced solid tumors.
- Trial name
- NCT06644755
- Testing
- DS-2243a
- Where
- 7 sites in United States, Belgium and 3 more
- Volunteers
- 150 people
- Sponsor
- Daiichi Sankyo
Neoplasms
Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
To assess the safety, tolerability and determine recommended phase 2 dose (RP2D) of GSK3845097 in HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 positive participants with New York esophageal squamous cell carcinoma (NY-ESO)-1…
- Trial name
- NCT05943990
- Testing
- GSK3845097, Cyclophosphamide, Fludarabine
- Where
- 21 sites in United States, Australia and 4 more
- Volunteers
- 5 people
- Sponsor
- Adaptimmune
Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
This is an open label, two-stratum, phase 2 clinical trial evaluating the efficacy of 9-ING-41 in combination with gemcitabine/docetaxel in patients ≥10 years of age with advanced sarcoma.
- Conditions
- Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, Leiomyosarcoma
- Trial name
- NCT05116800
- Testing
- Gemcitabine, 9-ING-41, Docetaxel
- Where
- 2 sites in United States
- Sponsor
- Brown University
Sarcoma
Circulating " Cancer Cells / Macrophage " HYbrid Cells in Patients With Sarcoma?
Pilot, prospective, monocentric study aimed at evaluating the rate of patients with circulating "cancer cell/macrophage" hybrid cells in the peripheral blood.
- Trial name
- SAMHY SARCOME (NCT04512495)
- Testing
- Blood samples will be collected at two times :
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Institut Claudius Regaud
Sarcoma
Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether ifosfamide or doxorubicin is more effective for advanced or metastatic soft…
- Trial name
- NCT00003212
- Testing
- doxorubicin hydrochloride, ifosfamide
- Where
- 23 sites in Belgium, Denmark and 8 more
- Volunteers
- 780 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Sarcoma
Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery.
- Trial name
- VORTEX (NCT00423618)
- Testing
- radiotherapy
- Where
- 6 sites in United Kingdom
- Volunteers
- 216 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Endometrial Cancer, Ovarian Cancer
Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have advanced…
- Conditions
- Endometrial Cancer, Ovarian Cancer, Sarcoma
- Trial name
- NCT00003718
- Testing
- temozolomide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Sarcoma, HER-2 Protein Overexpression
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
The purpose of this study is to learn whether it is safe to give HER2-CAR T cells in combination with an immune checkpoint inhibitor drug (pembrolizumab or nivolumab), to learn what the side effects are, and to see whether this…
- Conditions
- Sarcoma, HER-2 Protein Overexpression, Osteosarcoma, Rhabdomyosarcoma
- Trial name
- NCT04995003
- Testing
- T cells or CAR T cells, Pembrolizumab Injectable Product, Nivolumab Injectable Product
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Baylor College of Medicine